Search

Your search keyword '"Ciardiello F"' showing total 139 results

Search Constraints

Start Over You searched for: Author "Ciardiello F" Remove constraint Author: "Ciardiello F" Topic medicine Remove constraint Topic: medicine
139 results on '"Ciardiello F"'

Search Results

1. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

2. Cancer diagnosis in patients with heart failure

Catalog

Books, media, physical & digital resources

3. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

4. The current and future role of the medical oncologist in the professional care for cancer patients

5. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer

6. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

7. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

8. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

9. KRAS early testing: Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting

10. Manuale di Oncologia Clinica

11. An update of new targets for cancer treatment: Receptor-mediated signals

12. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

13. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

14. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

15. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

16. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients

17. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

18. A Preliminary Study for Quantitative Assessment with HFUS (High- Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience

19. Primary cutaneous DLBCL non-GCB type: challenges of a rare case

20. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

21. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma

22. Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants

23. Use of rituximab in NHL malt type pregnant in I° trimester for two times

24. Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management

25. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

26. Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer

27. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

28. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials

29. Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results

30. Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

31. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

32. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

33. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

34. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data

35. Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial

36. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

37. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1

38. PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

39. How we treat metastatic colorectal cancer

40. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’

41. Towards the era of precision medicine in metastatic colorectal cancer

42. Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report

43. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists

44. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

45. Early triple negative breast cancer: Conventional treatment and emerging therapeutic landscapes

46. Central Nervous System as Possible Site of Relapse in ERBB2 -Positive Metastatic Colorectal Cancer: Long-term Results of Treatment with Trastuzumab and Lapatinib

47. Differential diagnosis: Retroperitoneal fibrosis and oncological diseases

48. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

49. It is finally time for adjuvant therapy in melanoma

50. Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors